NO306905B1 - Oligosakkarid avledet fra antigent polysakkarid erholdt fra et patogen - Google Patents

Oligosakkarid avledet fra antigent polysakkarid erholdt fra et patogen

Info

Publication number
NO306905B1
NO306905B1 NO932102A NO932102A NO306905B1 NO 306905 B1 NO306905 B1 NO 306905B1 NO 932102 A NO932102 A NO 932102A NO 932102 A NO932102 A NO 932102A NO 306905 B1 NO306905 B1 NO 306905B1
Authority
NO
Norway
Prior art keywords
pathogen
polysaccharide obtained
antigenic polysaccharide
oligosaccharide derived
derived
Prior art date
Application number
NO932102A
Other languages
English (en)
Norwegian (no)
Other versions
NO932102L (no
NO932102D0 (no
Inventor
Monique Moreau
Original Assignee
Pasteur Merieux Serums Vacc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Merieux Serums Vacc filed Critical Pasteur Merieux Serums Vacc
Publication of NO932102D0 publication Critical patent/NO932102D0/no
Publication of NO932102L publication Critical patent/NO932102L/no
Publication of NO306905B1 publication Critical patent/NO306905B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
NO932102A 1991-10-10 1993-06-09 Oligosakkarid avledet fra antigent polysakkarid erholdt fra et patogen NO306905B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9112478A FR2682388B1 (fr) 1991-10-10 1991-10-10 Procede de preparation d'un oligoside par depolymerisation d'un polyoside issu d'un agent pathogene, oligoside ainsi obtenu et son utilisation notamment comme agent vaccinal.
PCT/FR1992/000955 WO1993007178A1 (fr) 1991-10-10 1992-10-09 Oligoside derive d'un polyoside antigenique issu d'un agent pathogene

Publications (3)

Publication Number Publication Date
NO932102D0 NO932102D0 (no) 1993-06-09
NO932102L NO932102L (no) 1993-08-05
NO306905B1 true NO306905B1 (no) 2000-01-10

Family

ID=9417772

Family Applications (1)

Application Number Title Priority Date Filing Date
NO932102A NO306905B1 (no) 1991-10-10 1993-06-09 Oligosakkarid avledet fra antigent polysakkarid erholdt fra et patogen

Country Status (15)

Country Link
US (2) US6045805A (de)
EP (1) EP0562107B1 (de)
JP (1) JP3676803B2 (de)
KR (1) KR100249709B1 (de)
AT (1) ATE217015T1 (de)
AU (1) AU661071B2 (de)
CA (1) CA2098105C (de)
DE (1) DE69232585T2 (de)
DK (1) DK0562107T3 (de)
ES (1) ES2174839T3 (de)
FI (1) FI110164B (de)
FR (1) FR2682388B1 (de)
HU (1) HU219672B (de)
NO (1) NO306905B1 (de)
WO (1) WO1993007178A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69331495T2 (de) * 1992-08-31 2002-10-31 Baxter Healthcare S.A., Wallisellen Impfstoffe gegen neisseria meningitidis gruppe c
KR100293017B1 (ko) * 1992-09-24 2001-09-17 루시에 라포인테-쇼우, 카르타 커티 케이 그룹b스트렙토코쿠스ii형및v형다당류-단백질결합백신
US5514665A (en) * 1993-12-30 1996-05-07 University Of British Columbia Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
US5738855A (en) * 1994-10-17 1998-04-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide
US6284884B1 (en) 1995-06-07 2001-09-04 North American Vaccine, Inc. Antigenic group B streptococcus type II and type III polysaccharide fragments having a 2,5-anhydro-D-mannose terminal structure and conjugate vaccine thereof
US5811102A (en) 1995-06-07 1998-09-22 National Research Council Of Canada Modified meningococcal polysaccharide conjugate vaccines
FR2748476B1 (fr) * 1996-05-07 1998-08-14 Pf Medicament Complexe immunogene, son utilisation, son procede de preparation et vaccin le contenant
US5965714A (en) * 1997-10-02 1999-10-12 Connaught Laboratories, Inc. Method for the covalent attachment of polysaccharides to protein molecules
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
EP1035137A1 (de) * 1999-03-12 2000-09-13 Pasteur Merieux Serums Et Vaccins Verfahren zur reduktiven aminierung von polysacchariden
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
FR2806304B1 (fr) * 2000-03-17 2002-05-10 Aventis Pasteur Conjugues polysaccharidiques du pneumocoque a usage vaccinal contre le tetanos et la diphterie
HU230490B1 (hu) 2001-01-23 2016-08-29 Sanofi Pasteur Inc. Multivalens, meningokokkusz-eredetű poliszaccharid és fehérje konjugátumát tartalmazó vakcina
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
EP2284535A1 (de) 2002-03-11 2011-02-16 Momenta Pharmaceuticals, Inc. Heparine mit niedrigem Molekulargewicht
DE60325565D1 (de) * 2002-03-26 2009-02-12 Novartis Vaccines & Diagnostic Modifizierte saccharide mit verbesserter stabilität in wasser
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
US20060251675A1 (en) * 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
WO2005000345A2 (en) 2003-06-23 2005-01-06 Aventis Pasteur, Inc. Immunization method against neisseria meningitidis serogroups a and c
WO2005044861A1 (en) * 2003-10-31 2005-05-19 Wyeth Holdings Corporation Polysaccharides of helicobacter pylori
US20060039899A1 (en) * 2004-08-23 2006-02-23 Winn Robert T Animal nutritional product that increases weight gain and reduces diarrhea morbidity, mortality and severity by stimulation of natural immune response, nutritional support of immune function and supplemental nutricines and probiotics
FR2884830A1 (fr) * 2005-04-25 2006-10-27 Sanofi Pasteur Sa Procede de production de souches de staphylococcus aureus surproductrices
FR2899110A1 (fr) * 2006-03-31 2007-10-05 Sanofi Pasteur Sa Polysaccharides capsulaires de type 5 et de type 8 des souches surproductrices de staphylococcus aureus
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
ES2812523T3 (es) 2009-09-30 2021-03-17 Glaxosmithkline Biologicals Sa Conjugación de polisacáridos capsulares de Staphylococcus aureus de tipo 5 y de tipo 8
MX2012004851A (es) 2009-10-30 2012-05-22 Novartis Ag Purificacion de sacaridos capsulares de staphylococcus aureus tipo 5 y tipo 8.
US8435795B2 (en) * 2010-01-19 2013-05-07 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
WO2012115952A1 (en) 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
EP2870974A1 (de) 2013-11-08 2015-05-13 Novartis AG Salmonella-Konjugatimpfstoffe
EP4309670A3 (de) 2016-09-02 2024-07-17 Sanofi Pasteur, Inc. Neisseria-meningitidis-impfstoff
CN116870144A (zh) 2017-01-31 2023-10-13 默沙东有限责任公司 制备多糖-蛋白缀合物的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) * 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates
US4673574A (en) * 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
SE8200751L (sv) * 1982-02-09 1983-08-10 Olle Larm Forfarande for kovalent koppling for framstellning av konjugat och hervid erhallna produkter
NL8202527A (nl) * 1982-06-22 1984-01-16 Univ Utrecht Vaccins tegen door bacterien met kapsel-polysacchariden verwekte ziekten en werkwijze voor het bereiden daarvan.
US4663160A (en) * 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4762713A (en) * 1983-07-05 1988-08-09 The University Of Rochester Boosting of immunogenic conjugate vaccinations by unconjugated bacterial capsular polymers
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) * 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1214609B (it) * 1985-05-17 1990-01-18 Opocrin Spa Esosaminoglicani solfati depolimerizzati ad attivita'antitrombotica, fibrinolitica, antinfiammatoria, loro procedimento di preparazione e composizioni farmaceutiche che li contengono.
IT1187753B (it) * 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
EP0282482B1 (de) * 1985-10-24 1992-01-22 Medical Research Council Biochemisches reagenzmittel
US5302386A (en) * 1986-04-16 1994-04-12 Brigham And Women's Hospital, Inc. Bacterial antigens, antibodies, vaccines and methods of manufacture
DE3750139T2 (de) * 1986-04-16 1994-10-06 Brigham & Womens Hospital Bakterielle antigene, antikörper, impfstoffe und deren herstellung.
AR243540A1 (es) * 1986-08-05 1993-08-31 Ajorca Sa Procedimiento quimico para la depolimerizacion controlada de polianiones naturales y productos asi obtenidos, excluidos sus usos farmaceuticos.
US5204098A (en) * 1988-02-16 1993-04-20 The United States Of America As Represented By The Department Of Health And Human Services Polysaccharide-protein conjugates
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5476929A (en) * 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US5370872A (en) * 1991-08-12 1994-12-06 Swiss Serum And Vaccine Institute Berne Escherichia coliO-polysaccharide-protein conjugate vaccine
US5445817A (en) * 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines

Also Published As

Publication number Publication date
JPH06506233A (ja) 1994-07-14
HUT70298A (en) 1995-09-28
FI932626A0 (fi) 1993-06-09
CA2098105C (fr) 2003-04-29
NO932102L (no) 1993-08-05
ES2174839T3 (es) 2002-11-16
DE69232585D1 (de) 2002-06-06
AU2946992A (en) 1993-05-03
ATE217015T1 (de) 2002-05-15
CA2098105A1 (fr) 1993-04-10
FI932626A (fi) 1993-06-09
DE69232585T2 (de) 2002-12-05
FI110164B (fi) 2002-12-13
AU661071B2 (en) 1995-07-13
KR930703362A (ko) 1993-11-29
US6045805A (en) 2000-04-04
FR2682388B1 (fr) 1995-06-09
HU219672B (hu) 2001-06-28
KR100249709B1 (ko) 2000-03-15
DK0562107T3 (da) 2002-08-19
NO932102D0 (no) 1993-06-09
EP0562107A1 (de) 1993-09-29
EP0562107B1 (de) 2002-05-02
JP3676803B2 (ja) 2005-07-27
US6007818A (en) 1999-12-28
HU9301682D0 (en) 1993-10-28
FR2682388A1 (fr) 1993-04-16
WO1993007178A1 (fr) 1993-04-15

Similar Documents

Publication Publication Date Title
NO306905B1 (no) Oligosakkarid avledet fra antigent polysakkarid erholdt fra et patogen
DE69531699D1 (de) Cyclodextrinderivate und verfahren zu deren herstellung
AU4841693A (en) Vaccines against group c neisseria meningitidis
FI914564A (fi) Foerbaettrade konjugerade oligosackaridvacciner.
FI923023A0 (fi) Implantationsmaterial aostadkommande naervaskularisation.
NO975387L (no) Fremgangsmåte for fremstilling av 3-haloalkyl-1H-pyrazoler
FI99086C (fi) Ultraäänivarjoaineita, menetelmä niiden valmistamiseksi ja niiden käyttö diagnostisina aineina
DK0550477T3 (da) Inaktiveret Mycoplasma hyopneumoniae-bakterin og fremgangsmåde til anvendelse deraf
BG104329A (en) New method of treatment
EA199900342A1 (ru) Способ создания активного иммунитета вакцинным конъюгатом
ATE244578T1 (de) Behandlung eines durch helicobakter verursachten gastroduodenalen krankheit
ATE222930T1 (de) Antigene arznei zur behandlung oder vorbeugung
YU63696A (sh) Novi fenilamidin-derivati, postupci za njihovo pripremanje i njihova primena kao lekova
DK0787135T3 (da) Vandopløslige derivater af epipodophyllotoxin, fremgangsmåde til fremstilling deraf og anvendelse som et lægemiddel til beh
EP0836480A4 (de) Zusammensetzungen, welche adp-ribosyltransferase-aktivität ausweisen und methoden für ihre herstellung und die verwendung derselben
ES2042021T3 (es) Nuevo procedimiento de preparacion de derivados trifluorometilvinilicos a partir de derivados halogenovinilicos correspondientes.
IL117151A0 (en) Novel antigen
UA42681C2 (uk) Вакцина проти трихофітії тварин
DE59704477D1 (de) Pharmazeutische antigen-/antikörperpräparation
UA67685A (en) Method for treating infection-associated antiphospholipid syndrome in recurrent abortion
MX9708226A (es) Vacunas que contienen una saponina y un esterol.

Legal Events

Date Code Title Description
MK1K Patent expired